Summary
We examined the influence of hormone replacement therapy (HRT) on breast tumour biology by comparing the prognostic characteristics of breast cancers and survival in 121 women prescribed replacement hormones before diagnosis with those in 1468 women without such treatment. The women receiving HRT had a lowered relative risk of being diagnosed with tumours of more than 20 mm in diameter, OR = 0.7 (CI 0.5–1.0) and axillary lymph node dissemination, OR = 0.7 (CI 0.4–1.1). These risk reductions were most pronounced and statistically significant in the women who had been prescribed a combined estradiol-progestin regimen. The patients in this compound group also had a diminished relative risk of having poorly differentiated tumours. Further, there was an indication that the women prescribed HRT, and especially those with conjugated estrogens/estradiols alone, had a decreased relative risk of developing aneuploid tumours. There was no clear pattern for women receiving the biologically weak oestriol, although risk estimates were generally higher for unfavourable tumours in comparison with those receiving the higher potency compounds. Adjustments for indications of earlier detection (i.e. lead time bias) did not influence the pattern or magnitude of the risk estimates. No association between any type of HRT and survival after breast cancer diagnosis was noted, but analyses were based only on 19 breast cancer deaths among exposed patients. We conclude that breast cancers occurring after treatment with HRT, especially the combined estrogen-progestin regimen, seem to have more favourable tumour features than tumours in non-treated women. Our findings may reflect a less aggressive biological behaviour of breast cancers in women receiving HRT, or in part be explained by the earlier detection of the tumours in these women.
References
Dupont WD, Page DL: Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 151: 67–72, 1991
Steinberg KK, Thacker SB, Smith SJ, Stroup DF, Zack MM, Flanders WD, Berkelman RL: A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 15: 1985–1990, 1991
Yuen J, Persson I, Bergkvist L, Hoover R, Schairer C, Adami HO: Hormone replacement therapy and breast cancer mortality in Swedish women. Results after adjustment for ‘healthy drug user effect’. Cancer Causes Control 4: 369–374, 1993
Hunt K, Vessey M, McPhersson K: Mortality in cohort of long-term users of hormone replacement therapy: an updated analysis. Br J Ob Gyn 97: 1080–1086, 1990
Henderson BE, Paganini-Hill A, Ross RK: Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 151: 75–78, 1991
Brinton LA, Hoover R, Fraumeni JF Jr: Menopausal estrogens and breast cancer risk: an expanded case-control study. Br J Cancer 54: 825–832, 1986
Bergkvist L, Adami HO, Persson I, Bergström R, Krusemo UB: Prognosis after breast cancer diagnosed in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol 130: 221–228, 1989
Persson I, Adami HO, Johansson EDB, Lindberg BL, Manell P, Westerholm B: A cohort study of oestrogen treatment and the risk of endometrial cancer: evaluation of method and its applicability. Eur J Clin Pharmacol 25: 625–632, 1983
Ackerman LV: Surgical Pathology. CV Mosby, St. Louis, 1968, p 736
Auer G, Caspersson T, Wallgren A: DNA content and survival in mammary carcinoma. Annal Quant Cytol 3: 161–165, 1980
Strang P: Comparison between flow cytometry and single cell cytophotometry for DNA content analysis of the uterine cervix. Acta Radiol Oncol 24: 337–341, 1985
Wrange Ö, Nordenskjöld B, Gustafsson JÅ: Cytosol estradiol receptor in human mammary carcinoma: an assay based on isoelectric focusing in polyacrylamide gel. Annal Biochem 85: 461–475, 1978
Breslow N, Day N: Statistical Methods in Cancer Research. Vol 1. The analysis of case-control studies. IARC, Lyon, 1980
Holmberg L, Adami HO, Ekbom A, Sandström A, Bergström R: Prognostic significance of the Ackerman classification and other histopathological characteristics in breast cancer. An analysis of 1,349 consecutive cases with complete follow up over seven years. APMIS 96: 979–990, 1988
Galea MH, Blamey RW, Elston CW, Ellis IO: The Nottingham prognostic index in primary breast cancer. Breast Cancer Res Treat 22: 207–219, 1992
Todd JH, Dowle C, Williams MR, Elston CW, Ellis IO, Hinton CP, Blamey RW, Haybittle JL: Confirmation of a prognostic index in primary breast cancer. Br J Cancer 56: 489–492, 1987
Crowe J, Gordon N, Shenk R, Zollinger R, Brumberg D, Shuck J: Primary tumour size: relevance to breast cancer survival. Arch Surg 127: 910–916, 1992
McGuire WL: Prognostic factors for recurrence and survival in human breast cancer. Breast Cancer Res Treat 10: 5–9, 1987
Toikkanen S, Joensuu H, Klemi HP: The prognostic significance of nuclear DNA content in invasive breast cancer — a study with long-term follow-up. Br J Cancer 60: 693–700, 1989
Nordén T, Holmberg L, Lindgren A, Bergström R, Adami HO: Hormone receptors, DNA ploidy and prognosis in operable breast cancer patients given no adjuvant treatment. The Breast, in press
Colditz GA, Stampfer MJ, Willett WC, Hunter DJ, Manson JE, Hennekkens CH, Rosner BA, Speizer FE: Type of postmenopausal hormone use and risk of breast cancer: 12-year follow-up from the Nurses' Health Study. Cancer Causes Control 3: 433–439, 1992
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Magnusson, C., Holmberg, L., Nordén, T. et al. Prognostic characteristics in breast cancers after hormone replacement therapy. Breast Cancer Res Tr 38, 325–334 (1996). https://doi.org/10.1007/BF01806152
Issue Date:
DOI: https://doi.org/10.1007/BF01806152